NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

Remicade生物仿製藥市場:COVID-19的影響分析:各技術,各用途,各地區 - 規模,佔有率,預測(2021年∼2027年)

Remicade Biosimilar Market with COVID-19 Impact Analysis, By Technology, By Application, and By Region - Size, Share, & Forecast from 2021-2027

出版商 AnalystView Market Insights 商品編碼 1023693
出版日期 內容資訊 英文 321 Pages
商品交期: 2-3個工作天內
價格
Remicade生物仿製藥市場:COVID-19的影響分析:各技術,各用途,各地區 - 規模,佔有率,預測(2021年∼2027年) Remicade Biosimilar Market with COVID-19 Impact Analysis, By Technology, By Application, and By Region - Size, Share, & Forecast from 2021-2027
出版日期: 2021年08月01日內容資訊: 英文 321 Pages
簡介

全球Remicade生物仿製藥的市場規模2021∼2027年的預測期間內預計將以8.9%的年複合成長率擴大。

隨著斑塊狀銀屑病和類風濕性關節炎等自身免疫性疾病的發病率上升,Remicade 生物仿製藥行業預計將擴大。此外,這些生物仿製藥以靜脈注射方式的可用性預計將在整個預測期內促進 Remicade 生物仿製藥的採用。

本報告提供Remicade生物仿製藥市場相關調查,提供市場概要,以及各技術,各用途,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 Remicade生物仿製藥市場市場概要

第2章 摘要整理

  • 市場明細
    • 各技術的市場明細
    • 各用途的市場明細
    • 各地區的市場明細
  • 競爭考察

第3章 Remicade生物仿製藥的主要市場趨勢

  • 市場推動因素
    • 市場成長要素的影響分析
  • 市場阻礙因素
    • 市場阻礙因素的影響分析
  • 市場機會
  • 市場未來趨勢

第4章 Remicade生物仿製藥產業調查

  • 波特的五力分析
  • 行銷策略分析
  • 成長預測製圖
  • 法律規範分析

第5章 Remicade生物仿製藥市場:COVID-19影響分析

  • COVID-19前的影響分析
  • COVID-19後的影響分析
    • 最高收益市場區隔
    • 邊際成長市場區隔
    • 最低收益市場區隔
    • 邊際損失市場區隔

第6章 Remicade生物仿製藥市場形勢

  • 市場佔有率分析,2019年
  • 關鍵創新者分析
  • 各主要製造商的明細資料
    • 固有企業分析
    • 新興企業分析

第7章 Remicade生物仿製藥市場-各技術

  • 概要
  • 重組DNA技術(rDNA技術)
  • 單株抗體(MAb)技術

第8章 Remicade生物仿製藥市場-各用途

  • 概要
  • 血液學
  • 腫瘤學
  • 自體免疫疾病
  • 關節炎
  • 發炎性腸道疾病(IBD)
  • 潰瘍性大腸炎
  • 克隆氏症
  • 生長激素缺乏症
  • 糖尿病
  • 其他

第9章 Remicade生物仿製藥市場-各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區(APAC)
  • 南美
  • 中東和非洲

第10章 供應商分析

  • 競爭力儀表板
  • 企業簡介
    • Alvogen
    • Celltrion,
    • Johnson &Johnson
    • Janssen Biotech, Inc.,
    • Merck and Company, Inc.
    • Napp Pharmaceuticals
    • Nippon Kayaku
    • Pfizer

第11章 分析師全方位展望

第12章 附錄

目錄
Product Code: ANV574

REPORT HIGHLIGHT

The global Remicade biosimilar market was valued at USD XX billion by 2019, growing with 8.9% CAGR during the forecast period, 2021-2027.

A biosimilar is a biological product that is very similar to a previously FDA-approved medicine, often known as a reference biological product. Biosimilars are medicines that have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and have no clinically significant variations from the reference product in terms of safety, purity, efficacy, or effectiveness.

These biosimilar medicines can only be approved for indications and conditions that have already been approved by major regulatory agencies for the reference product. Remicade (infliximab) is a monoclonal antibody developed in collaboration between Janssen Biotech Inc. and Merck & Co. (MSD) and approved by the US Food and Drug Administration in 1998. It is used for the treatment of Crohn's disease in both adults and children. It's also used to treat active ulcerative colitis, moderate to severe rheumatoid arthritis, spinal and active psoriatic arthritis, and plaque psoriasis.

For the treatment of a wide range of illnesses, there is a significant need for biological products. Biosimilar products, on the other hand, are becoming increasingly popular as a way to save healthcare expenditures. When compared to the original goods, biosimilar products are developed from biological products and have similar safety, efficacy, purity, and effectiveness. A biosimilar is a type of biologic product that is extremely similar to an FDA-approved biologic medicine known as a reference drug. Biosimilars are medicines that have been authorized by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and have no clinically significant differences from the reference biological product.

The Remicade biosimilar industry is projected to expand as the frequency of autoimmune disorders such as plaque psoriasis and rheumatoid arthritis rises. According to the American Autoimmune Related Disease Association, autoimmune disorders affected about 50 million Americans in 2017. Furthermore, the availability of these biosimilars in the form of intravenous mode of administration is projected to enhance the adoption of Remicade biosimilars throughout the projection period, resulting in faster reaction rates.

The patent expiration of branded versions is projected to increase the number of biosimilars for their branded equivalents, resulting in increased demand for Remicade biosimilar. The industry is growing because to increased market competition, which has resulted in lower pricing for biosimilar goods. Biosimilar goods are being used to enhance patient's access to treatment by providing financial assistance, which is fuelling market expansion. Increasing healthcare spending, along with an increase in the prevalence of autoimmune diseases, is also driving market demand. However, the worldwide Remicade biosimilar market is likely to be constrained by strict regulatory restrictions for copycat development as well as adverse effects of these medications that put patients at risk of hospitalization. Serious adverse effects, as well as strict regulatory requirements for the development of biosimilar medicines, may stymie market expansion.

Regional Analysis:

The Remicade biosimilar market is dominated by Europe, followed by Japan and Latin America. The launch of the biosimilar version soon after the branded version's patent expires is the main cause for this. However, in markets throughout North America and other countries, a systematic and quicker medication review procedure is likely to provide commercial traction.

The creation of successful regional production and distribution strategies for Remicade biosimilars might be aided by strict regulatory approval procedures and simplified manufacturing standards, particularly in Central and South American countries. the existence of major market participants in the region, quick biosimilar penetration in the European market, and a high biosimilar acceptance rate owing to lower pricing. For example, the European Commission (EC) granted Sandoz, a Novartis company, permission for Zessly (infliximab), a Remicade copycat, to be used in Europe in 2018. Over the projected period, the market is likely to increase due to continued research and quick approvals by US regulatory agencies for biosimilar market entrance in North America.

Competitive Landscape:

The increased incidence of chronic illnesses attributable to expanding lifestyle-related behaviors and an increase in cigarette use patterns among millennials are expected to propel the Indian industry forwards. Furthermore, new healthcare facilities are being built, hospitals are being built, and private clinics are becoming more accepted, all of which have aided the industry's growth. Increased R&D operations in the nation by key players like Biocon, Zydus Cadila, and others would also boost biosimilar sales.

Key features of the study:

This proposed research study on Remicade biosimilar market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2020-2027), considering 2019 as the base year

The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Remicade biosimilar market

The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Remicade biosimilar market

Impact of COVID-19 on Remicade biosimilar market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Remicade biosimilar market post-COVID will also be covered.

In order to give the users of this report a comprehensive view on the Remicade biosimilar market, we have also included competitive landscape and key innovator analysis for the Remicade biosimilar market.

The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and end-user's attractiveness.

The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Remicade biosimilar market.

In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new product launch, research & development, regional expansion of major participants involved in the Remicade biosimilar market on global as well as regional level.

The global Remicade biosimilar market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL REMICADE BIOSIMILAR MARKET KEY PLAYERS

Alvogen

Celltrion,

Johnson & Johnson

Janssen Biotech, Inc.,

Merck and Company, Inc.

Napp Pharmaceuticals

Nippon Kayaku

Pfizer

GLOBAL REMICADE BIOSIMILAR MARKET, BY TECHNOLOGY

Recombinant DNA Technology (rDNA technology)

Monoclonal Antibodies (MAb) Technology

GLOBALREMICADE BIOSIMILAR MARKET, BY APPLICATION TYPE

Hematology

Oncology

Autoimmune Disease

Arthritis

Inflammatory Bowel Disease (IBD)

Ulcerative Colitis

Crohn's Disease

Growth Hormone Deficiency

Diabetes

Others

GLOBAL REMICADE BIOSIMILAR MARKET, BY REGION

North America

The U.S.

Canada

Europe

Germany

France

Italy

Spain

United Kingdom

Rest of Europe

Asia Pacific

India

China

South Korea

Japan

Singapore

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

The Middle East and Africa

Saudi Arabia

United Arab Emirates

Rest of MEA

TABLE OF CONTENT

1. Remicade Biosimilar Market Overview

  • 1.1. Study Scope

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Market Snippet by Technology
    • 2.1.2. Market Snippet by Application
    • 2.1.3. Market Snippet by Region
  • 2.2. Competitive Insights

3. Remicade Biosimilar Key Market Trends

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. Remicade Biosimilar Industry Study

  • 4.1. Porter's Five Forces Analysis
  • 4.2. Marketing Strategy Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Remicade Biosimilar Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Remicade Biosimilar Market Landscape

  • 6.1. Market Share Analysis, 2019
  • 6.2. Key Innovators Analysis
  • 6.3. Breakdown Data, by Key Manufacturer
    • 6.3.1. Established Players' Analysis
    • 6.3.2. Emerging Players' Analysis

7. Remicade Biosimilar Market - By Technology

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Technology, 2020 & 2027 (%)
  • 7.2. Recombinant DNA Technology (rDNA technology)
  • 7.3. Monoclonal Antibodies (MAb) Technology

8. Remicade Biosimilar Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2020 & 2027 (%)
  • 8.2. Hematology
  • 8.3. Oncology
  • 8.4. Autoimmune Disease
  • 8.5. Arthritis
  • 8.6. Inflammatory Bowel Disease (IBD)
  • 8.7. Ulcerative Colitis
  • 8.8. Crohn's Disease
  • 8.9. Growth Hormone Deficiency
  • 8.10. Diabetes
  • 8.11. Others

9. Remicade Biosimilar Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2020 & 2027 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 1.1.1.1. Canada Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 1.1.1.2. Canada Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.3.10. Rest of Europe
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.3.10.3. Rest of the Europe Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.3.10.4. Rest of the Europe Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.4.10. Rest of APAC
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.4.10.3. Rest of APAC Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.4.10.4. Rest of APAC Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.5.9. Rest of LATAM
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.5.9.3. Rest of LATAM Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.5.9.4. Rest of LATAM Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Technology, 2016 - 2027 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)

10. Key Vendor Analysis

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Alvogen
    • 10.2.2. Celltrion,
    • 10.2.3. Johnson & Johnson
    • 10.2.4. Janssen Biotech, Inc.,
    • 10.2.5. Merck and Company, Inc.
    • 10.2.6. Napp Pharmaceuticals
    • 10.2.7. Nippon Kayaku
    • 10.2.8. Pfizer

11. 360 Degree AnalystView

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Remicade Biosimilar market: Technologys Snapshot (2019)
  • TABLE Segment Dashboard; Definition and Scope, by Technologys
  • TABLE Global Remicade Biosimilarmarket, by Technologys2016-2027 (USD Million)
  • TABLE Remicade Biosimilar market: ApplicationSnapshot (2019)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Remicade Biosimilar market, by Application2016-2027 (USD Million)
  • TABLE Remicade Biosimilar market: Regional snapshot (2019)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Remicade Biosimilarmarket, by Region 2016-2027 (USD Million)
  • TABLE North America Remicade Biosimilarmarket, by Country, 2016-2027 (USD Million)
  • TABLE North America Remicade Biosimilar market, by Technologys, 2016-2027 (USD Million)
  • TABLE North America Remicade Biosimilar market, by Application, 2016-2027 (USD Million)
  • TABLE Europe Remicade Biosimilar market, by Country, 2016-2027 (USD Million)
  • TABLE Europe Remicade Biosimilar market, by Technologys, 2016-2027 (USD Million)
  • TABLE EuropeRemicade Biosimilar market, by Application, 2016-2027 (USD Million)
  • TABLE Asia Pacific Remicade Biosimilar market, by Country, 2016-2027 (USD Million)
  • TABLE Asia Pacific Remicade Biosimilar market, by Technologys, 2016-2027 (USD Million)
  • TABLE Asia Pacific Remicade Biosimilar market, by Application, 2016-2027 (USD Million)
  • TABLE Latin America Remicade Biosimilar market, by Country, 2016-2027 (USD Million)
  • TABLE Latin America Remicade Biosimilar market, by Technology, 2016-2027 (USD Million)
  • TABLE Latin America Remicade Biosimilar market, by Application, 2016-2027 (USD Million)
  • TABLE Middle East and Africa Remicade Biosimilar market, by Country, 2016-2027 (USD Million)
  • TABLE Middle East and Africa Remicade Biosimilar market, by Technology, 2016-2027 (USD Million)
  • TABLE Middle East and Africa Remicade Biosimilar market, by Application, 2016-2027 (USD Million)

List of Figures

  • FIGURE Remicade Biosimilarmarket segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2019
  • FIGURE Technology segment market share analysis, 2020 & 2027
  • FIGURE Technology segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Application segment market share analysis, 2020 & 2027
  • FIGURE Application segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Regional segment market share analysis, 2020 & 2027
  • FIGURE Regional segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE North America Remicade Biosimilar market share and leading players, 2019
  • FIGURE Europe Remicade Biosimilar market share and leading players, 2019
  • FIGURE Asia Pacific Remicade Biosimilarmarket share and leading players, 2019
  • FIGURE Latin America Remicade Biosimilarmarket share and leading players, 2019
  • FIGURE Middle East and Africa Remicade Biosimilarmarket share and leading players, 2019
  • FIGURE North America market share analysis by country, 2019
  • FIGURE U.S. Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Canada Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Europe Remicade Biosimilar market share analysis by country, 2019
  • FIGURE Germany Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Spain Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Italy Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE UK Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE France Remicade Biosimilarmarket size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Rest of the Europe Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Asia Pacific Remicade Biosimilar market share analysis by country, 2019
  • FIGURE India Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE China Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Japan Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE South Korea Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Singapore Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Rest of APAC Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Latin America Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Latin America Remicade Biosimilar market share analysis by country, 2019
  • FIGURE Brazil Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Mexico Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Argentina Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Rest of LATAM Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Middle East and Africa Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Middle East and Africa Remicade Biosimilar market share analysis by country, 2019
  • FIGURE Saudi Arabia Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE United Arab Emirates Remicade Biosimilar market size, forecast and trend analysis, 2016 to 2027 (USD Million)